Global Mammalian Polyclonal IgG Antibody Market Report
According to the global mammalian polyclonal IgG antibody market report by IMARC Group, the market reached a value of US$ 984.81 Million in 2021, and it is projected to reach a value of US$ 1,351.73 Million by 2027, exhibiting a CAGR of 5.25% during 2022-2027.
Mammalian polyclonal immunoglobulins (IgG) antibodies are antigens or vaccines made by inoculating numerous mammals, such as mice, rabbits, and goats. These antibodies are used to label the reagents in various immunoassay tests, such as the western blot tests, immunoradiometric assay (IRMA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). They perform flow cytometry and antibody identification and help develop numerous therapeutics and diagnose various ailments. As a result, mammalian polyclonal IgG antibodies find extensive applications in biochemical research to identify denatured proteins and examine diseases and their treatments across the globe.
The global mammalian polyclonal IgG antibody market is primarily driven by the rising prevalence of various chronic disorders, such as cancer and autoimmune ailments. Moreover, the increasing need for antibodies for numerous immunoassay tests and analytical and therapeutic purposes in research settings is positively influencing the market growth.
Request and get a sample brochure for free: https://www.imarcgroup.com/mammalian-polyclonal-igg-antibody-market/requestsample
Additionally, the ongoing development of innovative mammalian antibodies for quality control (QC) by biopharma organizations is another major growth-inducing factor. Furthermore, the rising investments by governments of numerous countries in biotechnology and pharmaceutical companies to manufacture effective novel vaccinations and injectables through advanced technologies have catalyzed market growth. Other factors, including ongoing research and development (R&D) activities, rising biomarkers approvals, and improvements in healthcare infrastructure, are also anticipated to drive the market further.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.
The report has been segmented the market into following categories:
Breakup by Type:
Breakup by Product:
- Cardiac Markers
- Metabolic Markers
- Renal Markers
Breakup by Application:
- Antibody Identification
- Western Blotting
Breakup by End Use:
- Diagnostic Centers
- Academic and Research Institutes
Breakup by End-Use Sector:
- Commercial and Industrial
Based on the end-use sector, the report finds that the utility sector dominates the market. There are many ongoing development projects undertaken by various nations, which require a continuous flow of electricity. Owing to this, there is a rising demand for power inverters in this sector.
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=6464&flag=C
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 |
Africa and Europe :- +44-702-409-7331 |
Asia: +91-120-433-0800, +91-120-433-0800